Destiny-breast01 nct03248492
WebFDA approval for Enhertu was based on the results of a multicenter, single-arm, clinical trial, DESTINY-Breast01 (NCT03248492), that enrolled 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had received two or more prior anti-HER2 therapies in the metastatic setting. Patients were excluded for a history ... WebFeb 2, 2024 · (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.) Approximately 15 to 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). 1–3 The recommended first-line therapy for HER2-positive …
Destiny-breast01 nct03248492
Did you know?
WebT-DXd has been approved for HER2-positive metastatic breast cancer and for HER2-positive metastatic gastric cancer. The approval in breast cancer was based on results from the DESTINY-Breast01 (U201; NCT03248492) and J101 (NCT02564900) trials. Here, we present dose justification for the approved 5.4 mg/kg every-3-weeks (Q3W) dose based … WebOn the basis of findings of the phase 2 DESTINY-Breast01 trial (NCT03248492), T-DXd was approved for the treatment of adult pts with HER2+ unresectable or mBC who have received ≥2 prior anti-HER2–based regimens (US and Europe) or had prior chemotherapy and are refractory to or intolerant of standard treatments (Japan).
WebDec 10, 2024 · “DESTINY-Breast02 confirms the favorable benefit-risk ratio of trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer.” The 12-month and 24-month PFS rates were 62.3% (95% CI, 57.0%-67.1%) and 42.2% (95% CI, 36.5%-47.8%) of patients who received trastuzumab deruxtecan. WebMay 28, 2024 · On the basis of findings of the phase 2 DESTINY-Breast01 trial (NCT03248492), T-DXd was approved for the treatment of adult pts with HER2+ unresectable or mBC who have received ≥2 prior anti-HER2–based regimens (US and Europe) or had prior chemotherapy and are refractory to or intolerant of standard …
WebDec 11, 2024 · Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrialsg. ov number, NCT03248492). ABSTRACT Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer WebNov 30, 2024 · Sara Hurvitz, MD:Before we discuss how this data should be implemented in our clinical practice, I'd like to discuss another poster that was presented at ESMO [European Society for Medical Oncology], the updated overall survival results from DESTINY-Breast01 [NCT03248492].Let’s talk about how you are using T-DXd in your …
WebJul 14, 2024 · The landmark phase 2 DESTINY-Breast01 trial (NCT03248492), showed that T-DXd had an objective response rate (ORR) of 61.4% and median progression-free survival (mPFS) of 19.4 months in patients with previously treated HER2+ advanced or metastatic breast cancer [2,3]. The trial allowed enrollment of patients with stable brain metastases, …
breathe indulgence and beauty aldgateWebFeb 2, 2024 · (Funded by Daiichi Sankyo and AstraZeneca; DESTINY-Breast01 ClinicalTrials.gov number, NCT03248492.) Approximately 15 to 20% of metastatic breast cancers are characterized by overexpression or amplification of human epidermal growth factor receptor 2 (HER2). 1–3 The recommended first-line therapy for HER2-positive … breathe indulgenceWebDec 20, 2024 · Efficacy was investigated in DESTINY-Breast01 (NCT03248492), a multicenter, single-arm trial enrolling 184 female patients with HER2-positive, unresectable and/or metastatic breast cancer who had... breathe in detroitWebNov 8, 2024 · In the phase 2 DESTINY-Breast01 trial (NCT03248492), investigators reported a median progression-free survival (PFS) of 16.4 months among 184 heavily pretreated patients. Responses were observed in 112 patients (60.9%); the disease control rate was 97.3%. 2 breathe in different languagesWebApr 30, 2024 · The safety of T-DXd was evaluated in a pooled analysis of 234 patients with HER2-positive breast cancer who received at least one dose of T-DXd 5.4 mg/kg in the DESTINY-Breast01 (NCT03248492), and in the phase 1 trial DS8201-A-J101 (NCT02564900) [9,10,22]. The most common adverse events (AE) (i.e., frequency … breathe indict demon fallWeb在 DESTINY-Breast01和DS8201-A-J101研究(NCT02564900)中，对234名接受了至少一剂曲妥珠单抗重组冻干粉注射剂 5.4mg/kg的不可切除或转移性HER2阳性乳腺癌患者的汇总分析中评估了安全性。曲妥珠单抗重组冻干粉注射剂i最常见的不良反应(频率≥20%)为恶心、疲劳、呕吐、脱发 ... cot pad coverWebAug 15, 2024 · Additionally, based on findings from the phase 2 DESTINY-Breast01 trial (NCT03248492), T-DXd was approved by the FDA for those with unresectable or metastatic HER2-positive breast cancer who have received 2 or more prior anti-HER2 therapies. co to znaczy there is